Literature DB >> 29464513

Lipids in RA: Is Less Not Necessarily More?

Jorge Plutzky1, Katherine P Liao2.   

Abstract

PURPOSE OF REVIEW: In rheumatoid arthritis (RA), lipid levels are dynamic and can fluctuate along with changes in inflammation. A reduction in inflammation, most commonly as a result of disease-modifying anti-rheumatic drug (DMARD) therapy, is associated with increases in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). In this review, we discuss new evidence shedding light on the potential mechanism underlying changes in lipid levels observed with changes in inflammation. RECENT
FINDINGS: Measured lipid levels in the blood are a result of a balance between synthesis and catabolism or absorption. Recent human studies in active RA show that the catabolic rates of lipids are higher than expected compared to expected rates in the general population. DMARD therapy appears to allow a return to baseline lower catabolic rates, resulting in an apparent increase in lipids. Increases in lipids observed with control of inflammation and RA treatment suggest a return to homeostasis. Studies are underway to understand the overall impact on cardiovascular risk in RA when lipid levels increase as a result of controlling inflammation.

Entities:  

Keywords:  Cardiovascular disease; Lipid metabolism; Lipids; Rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 29464513      PMCID: PMC5933529          DOI: 10.1007/s11926-018-0715-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  28 in total

1.  Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.

Authors:  Jamie Robertson; Duncan Porter; Naveed Sattar; Chris J Packard; Muriel Caslake; Iain McInnes; David McCarey
Journal:  Ann Rheum Dis       Date:  2017-09-15       Impact factor: 19.103

2.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

3.  Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.

Authors:  Daniel H Solomon; Elizabeth W Karlson; Eric B Rimm; Carolyn C Cannuscio; Lisa A Mandl; JoAnn E Manson; Meir J Stampfer; Gary C Curhan
Journal:  Circulation       Date:  2003-03-11       Impact factor: 29.690

4.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

5.  An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.

Authors:  Vijay U Rao; Andrey Pavlov; Micki Klearman; David Musselman; Jon T Giles; Joan M Bathon; Naveed Sattar; Janet S Lee
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

6.  Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.

Authors:  Anne G Semb; Ingar Holme; Tore K Kvien; Terje R Pedersen
Journal:  Rheumatology (Oxford)       Date:  2010-09-30       Impact factor: 7.580

Review 7.  Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.

Authors:  Jasvinder A Singh; Saba Beg; Maria Angeles Lopez-Olivo
Journal:  J Rheumatol       Date:  2010-10-15       Impact factor: 4.666

8.  Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism.

Authors:  Nicoletta Ronda; Daniela Greco; Maria Pia Adorni; Francesca Zimetti; Elda Favari; Gunnbjørg Hjeltnes; Knut Mikkelsen; Maria Orietta Borghi; Ennio Giulio Favalli; Rita Gatti; Ivana Hollan; Pier Luigi Meroni; Franco Bernini
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

9.  The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.

Authors:  Katherine P Liao; Martin P Playford; Michelle Frits; Jonathan S Coblyn; Christine Iannaccone; Michael E Weinblatt; Nancy S Shadick; Nehal N Mehta
Journal:  J Am Heart Assoc       Date:  2015-01-30       Impact factor: 5.501

10.  Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.

Authors:  Bruce W Kirkham; Mary Chester Wasko; Elizabeth C Hsia; Roy M Fleischmann; Mark C Genovese; Eric L Matteson; Hongjuan Liu; Mahboob U Rahman
Journal:  Ann Rheum Dis       Date:  2013-01-07       Impact factor: 19.103

View more
  6 in total

Review 1.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

2.  Circulating microRNA-23b as a new biomarker for rheumatoid arthritis.

Authors:  Xi Liu; Su Ni; Chenkai Li; Nanwei Xu; Wenyang Chen; Min Wu; Andre J van Wijnen; Yuji Wang
Journal:  Gene       Date:  2019-06-06       Impact factor: 3.688

3.  Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses' Health Study.

Authors:  Su H Chu; Jing Cui; Jeffrey A Sparks; Bing Lu; Sara K Tedeschi; Cameron B Speyer; LauraKay Moss; Marie L Feser; Lindsay B Kelmenson; Elizabeth A Mewshaw; Jess D Edison; Kevin D Deane; Clary Clish; Jessica Lasky-Su; Elizabeth W Karlson; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

Review 4.  Metabolic Profiling in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: Elucidating Pathogenesis, Improving Diagnosis, and Monitoring Disease Activity.

Authors:  Erika Dorochow; Michaela Köhm; Lisa Hahnefeld; Robert Gurke
Journal:  J Pers Med       Date:  2022-06-02

5.  Diet intervention improves cardiovascular profile in patients with rheumatoid arthritis: results from the randomized controlled cross-over trial ADIRA.

Authors:  Erik Hulander; Linnea Bärebring; Anna Turesson Wadell; Inger Gjertsson; Philip C Calder; Anna Winkvist; Helen M Lindqvist
Journal:  Nutr J       Date:  2021-01-23       Impact factor: 3.271

6.  Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Wenhui Xie; Shiyu Xiao; Yanrong Huang; Xiaoying Sun; Zhuoli Zhang
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-12-17       Impact factor: 5.346

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.